Know Cancer

forgot password

An Open-Label, Single Arm, Phase Ib/II Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma

Phase 2
18 Years
Not Enrolling

Thank you

Trial Information

An Open-Label, Single Arm, Phase Ib/II Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma

This is a single arm, open-label, Phase Ib/II study to evaluate the safety,
pharmacokinetics, pharmacodynamics, and efficacy of the oral AKT inhibitor GSK2110183 when
administered to subjects with proteasome inhibitor refractory MM.

During Part 1 of the study, dose escalation will follow a 3 + 3 dose escalation procedure
starting with an initial dosing regimen of 125 mg GSK2110183 with escalate to next dose
level with an increase of GSK2110183 less than or equal to 50% if DLTs are below a certain
level described in the protocol. Subjects will receive a single dose of GSK2110183 on Day
-3 of Cycle 0, followed by PK sampling over the next 72 hours. Cycle 1 may commence at any
time (but within 7 days) after collection of the 72 hour Cycle 0 PK sample. GSK2110183 will
be administered to subjects in sequential PK Cohorts on a continuous daily dosing schedule
in 21 day cycles until one of the Treatment Discontinuation Criteria is met. Sparse PK
sampling will also be collected during the first 8 cycles. Urine PK samples will be
collected prior to the first dose of GSK2110183 and as a 24-hour urine collection at
steady-state. The PK Cohorts will characterize the pharmacokinetics of GSK2110183 in plasma
and urine, as well as determine the RP2D of GSK2110183. The RP2D will be that dose that
provides adequate PK exposure and biologic activity without exceeding the MTD in MM subjects
as defined in the current study. GSK2110183 + bortezomib salvage therapy will not be given
to subjects who progress on GSK2110183 monotherapy in the PK Cohorts. Following the
completion of PK sampling in the PK Cohorts and the determination of a RP2D of GSK2110183,
Part 2 of the study will then commence at the RP2D.

Part 2 of the study will further evaluate the R2PD using a flexible 2-stage design with a
stopping rule to allow for early termination based on lack of efficacy at the end of Stage
1. GSK2110183 will be administered on a continuous daily dosing schedule in 21-day cycles
until one of the Treatment Discontinuation Criteria is met. Twenty subjects will be enrolled
in Stage 1, if no subject responds, the study will be stopped; otherwise, the study will
continue to enroll an additional 20 subjects in Stage 2. At the end of Stage 2, if 4 or
fewer of 40 subjects respond, the study will not be deemed as a success for the monotherapy.
Those subjects meeting the criteria for progression during Part 2 [as defined by the 2011
Report of the International Myeloma Workshop Consensus Panel 1], who also meet the
additional eligibility criteria for salvage therapy may proceed to GSK2110183 + bortezomib
salvage therapy. GSK2110183 + bortezomib salvage therapy will be continued until one of the
Treatment Discontinuation Criteria is met.

Exploratory PK/PD analyses may be performed in Part 1 and Part 2 to examine the potential
relationships between GSK2110183 pharmacokinetics and pharmacodynamic biomarkers (e.g.,
pAKT, pPRAS40 in the bone marrow), markers for disease activity in serum (e.g., beta-2
microglobulin, C-reactive protein), or blood-based cytokines and angiogenesis factors (e.g.,
IL-6, VEGF).

A secondary objective of this study is to determine whether the addition of bortezomib to
GSK2110183 has clinical activity in patients refractory to proteasome inhibitor therapy who
progress on single-agent GSK2110183 therapy.

Inclusion Criteria:

- Capable of giving written informed consent, which includes compliance with the
requirements and restrictions listed in the consent form.

- Male or female who is at least 18 years of age or older.

- Histologically confirmed diagnosis of secretory MM (must have measurable M protein in
serum or urine) with one or more of the following:

Serum M-protein count greater than or equal to 1 g/dL Urinary M-protein greater than or
equal to 200 mg/24 hours Serum free light chain (FLC) assay: involved FLC level greater
than or equal to 10 mg/dL (greater than or equal to 100 mg/L) and a serum FLC ratio
outside of normal range. Biopsy proven plasmacytoma

- Relapsed after 2 or more lines of systemic therapy including at least one proteasome
inhibitor (i.e., bortezomib, carfilzomib) and at least one immunomodulatory agent
(i.e., lenalidomide, pomalidomide) AND refractory to proteasome inhibitor therapy.
Subjects will be considered refractory to proteasome inhibitor therapy if they
experienced stable disease or progressive disease as the best response on their last
proteasome inhibitor containing therapy OR progressed within 60 days following two or
more cycles of proteasome inhibitor therapy. A line of therapy is generally
separated by disease progression from a preceding line of therapy; therefore, the
preparative regimen (with or without total body irradiation) and subsequent
autologous stem cell rescue used for an autologous stem cell transplant are
considered as one line of therapy.

- Subjects with a history of autologous stem cell transplant are eligible for study
participation provided the following eligibility criteria are met:

Transplant was more than 100 days prior to study enrolment No active infection Subject
meets the remainder of the eligibility criteria

- Performance status score of 0 to 2 according to Eastern Cooperative Oncology Group

- Able to swallow and retain oral medication.

- Fasting serum glucose less than126 mg/dL (<7 mmol/L). Subjects diagnosed previously
with diabetes mellitus type 2 must also meet the additional following criteria:

Diagnosis of diabetes greater than 6 months prior to enrollment Glycosylated hemoglobin
A1c (HbA1c) less than 8% at screening

- A female subject is eligible to participate if she is of the following:

Non-childbearing potential (i.e., physiologically incapable of becoming pregnant) defined
as premenopausal females with a documented tubal ligation or hysterectomy; or
postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable cases a
blood sample with simultaneous follicle stimulating hormone greater than 40 MlU/ml and
estradiol less than 40 pg/ml (less than 147 pmol/L) is confirmatory. Females on hormone
replacement therapy (HRT) and whose menopausal status is in doubt will be required to use
one of the contraception methods listed in the protocol if they wish to continue their HRT
during the study. Otherwise, they must discontinue HRT to allow confirmation of
post-menopausal status prior to study enrollment. For most forms of HRT, at least 2 to 4
weeks will elapse between the cessation of therapy and the blood draw; this interval
depends on the type and dosage of HRT. Following confirmation of their post-menopausal
status, they can resume use of HRT during the study without use of a contraceptive method.

Childbearing potential, has a negative serum pregnancy test during the screening period,
and agrees to use adequate contraception (methods listed in the protocol) from screening
until four weeks after the last dose of GSK2110183. Note: Oral contraceptives are not
reliable due to potential drug-drug interaction.

- Male subjects with female partners of childbearing potential must have had a prior
vasectomy or agree to use adequate contraception from the time of the first dose of
GSK2110183 until 3 months after the last dose of GSK2110183.

- Adequate organ function as defined by laboratory results within specific value ranges
listed in the protocol.

Inclusion criteria: Salvage Therapy with GSK2110183 and Bortezomib:

- Platelet count greater than or equal to 70 X 10^9/L

- A subject whose ANC is greater than 1000/mm^3 before GSK2110183 monotherapy but whose
ANC decreases below 1000/mm^3 at the time of transitioning to the salvage therapy is
allowed up to 14 days following interruption of GSK2110183 dosing for ANC to recover
to greater than or equal to 1000/mm^3.

Exclusion Criteria:

- Chemotherapy, radiotherapy, immunotherapy, or other anti-myeloma therapy within 14
days prior to the first dose of GSK2110183. In addition, any drug-related toxicity,
except for alopecia, should have recovered to Grade 1 or less.

- Use of an investigational drug within 14 days or 5 half-lives, whichever is longer,
preceding the first dose of GSK2110183.

- History of an allogeneic stem cell transplant. Subjects with a history of an
autologous stem cell transplant are NOT excluded if they meet Inclusion Criterion 5
(Subjects with a history of autologous stem cell transplant are eligible for...).

- Current use of a prohibited medication.

- Current use of oral corticosteroids, with the exception of inhaled or topical

- Anticoagulants (e.g., warfarin, low molecular weight heparin, direct thrombin
inhibitors) at therapeutic doses or at low doses (e.g., prophylactic) are permitted
only if the subject meets the partial thromboplastin time (PTT) and international
normalization ratio (INR) entry criteria. Anticoagulant use must be monitored in
accordance with local institutional practice.

- Presence of active GI disease or other condition that could affect GI absorption
(e.g., malabsorption syndrome) or predispose subject to GI ulceration.

- Any major surgery within the last 14 days.

- Unresolved toxicity (except alopecia) greater than or equal to Grade 2 National
Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0
(NCI-CTCAE v4) from previous anticancer therapy.

- Presence of greater than Grade 1 peripheral neuropathy.

- Type 1 diabetes mellitus.

- Any serious or unstable pre-existing medical, psychiatric, or other condition
(including laboratory abnormalities) that could interfere with subject's safety or
providing informed consent.

- Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated
respiratory, hepatic, renal, or cardiac disease, unstable hypertension).

- History of known human immunodeficiency virus infection.

- Subjects with a positive test for hepatitis B surface antigen or a positive test for
hepatitis C antibody are excluded, regardless of the viral load. If hepatitis C
antibody is positive, a confirmatory RIBA test may be performed. If the RIBA test is
negative, the subject is eligible for the study.

- Primary or metastatic malignancy of the central nervous system.

- Diagnosis of or treatment for another malignancy within 2 years of enrollment, with
the exception of complete resection of basal carcinoma or squamous cell carcinoma of
the skin, or an in situ malignancy.

- QTC interval greater than or equal to 470 msec. NOTE: If initial result is
prolonged, eligibility will be based on the average of manually calculated QTcF value
from 3 ECGs (e.g., obtain 2 more ECGs at least 5 minutes apart and calculate the
average of triplicate ECGs).

- Other clinically significant ECG abnormalities including 2nd degree (Type II) or 3rd
degree atrioventricular block.

- History of myocardial infarction, acute coronary syndromes (including unstable
angina), coronary angioplasty, or stenting or bypass grafting within the past 6

- Class III or IV heart failure as defined by the New York Heart Association [NYHA,
1994] functional classification system.

- Known hypersensitivity to GSK2110183, bortezomib, boron, and/or mannitol.

- Pregnant or lactating female.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Evaluate the safety and tolerability of GSK2110183 in subjects with proteasome inhibitor refractory MM.

Outcome Description:

Subjects with proteasome inhibitor refractory MM enrolled into Parts 1 and 2 will be evaluate for safety and tolerability of GSK2110183 by the assessment of adverse events and changes from baseline in safety assessments including laboratory parameters, vital signs, and electrocardiogram (ECG) parameters.

Outcome Time Frame:

Subjects will continue on the study from the date of randomization until the date of the first documented progression or when the subjects meet one of the Treatment Discontinuation Criteria and may be assessed on average up to 48 months.

Safety Issue:


Principal Investigator

GSK Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:



United States: Food and Drug Administration

Study ID:




Start Date:

November 2011

Completion Date:

November 2011

Related Keywords:

  • Cancer
  • bortezomib
  • AKT inhibitor
  • multiple myeloma
  • GSK2110183
  • hematologic malignancies
  • Multiple Myeloma
  • Neoplasms, Plasma Cell